Adult Dosing
Monitored anesthesia care sedation induction
- Healthy adults or ASA P1 or P2 patients
- 6.5 mg/kg IV x1; Max: 577.5 mg/dose
- For pts <60 kg, calculate dose based on 60 kg; see pkg insert for dose adjustments based on age, weight, systemic disease
- Elderly or ASA P3-P4 pts
- Give 75% of standard dose for healthy adults; Info: see pkg insert for dose adjustments based on age, weight, systemic disease
Monitored anesthesia care sedation maintenance
- Healthy adults or ASA P1 or P2 patients
- 1.6 mg/kg IV x1; may repeat not more than q4 minutes; titrate to achieve desired level of sedation; Max: 140 mg/dose
- For pts <60 kg, calculate dose based on 60 kg; see pkg insert for dose adjustments based on age, weight, systemic disease
- Elderly or ASA P3-P4 pts
- Give 75% of standard dose for healthy adults; Info: see pkg insert for dose adjustments based on age, weight, systemic disease
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
See Supplemental Patient Information
- Only persons trained in the administration of general anesthesia and not involved in the conduct of the diagnostic or therapeutic procedure are eligible for administration of this drug
- Continuously monitor sedated patients and readily keep availability of facilities for maintenance of a patent airway, providing artificial ventilation, administering supplemental oxygen, and instituting cardiovascular resuscitation
- Continuously monitor patients during sedation and through the recovery process for early signs of hypotension, apnea, airway obstruction, and/or oxygen desaturation
- Respiratory depression may occur. Provide supplemental oxygen for all patients receiving this drug. Individualized dosages for each patient and titrate to desired effect. Use lower doses in patients who are
65 yrs of age or in those who have severe systemic disease. Consider additive cardiorespiratory effects of narcotic analgesics and sedative hypnotic agents during concomitant use with this drug. Assess patients for their ability to demonstrate purposeful response while sedated with this drug as patients who are unable to do so may lose protective reflexes. Airway assistance maneuvers may be essential in the management of respiratory depression - Hypoxemia may occur. Patients having retained the ability to respond purposefully to their health care provider following administration this drug and patients treated with greater than the recommended dose are more prone for development of hypoxemia. Appropriately position patients and use supplemental oxygen in all patients to avoid risk of hypoxemia. Provide airway assistance maneuvers for the management of hypoxemia. Consider additive cardiorespiratory effects of narcotic analgesics and sedative hypnotic agents during concomitant use with this drug
- This drug is not studied for use in general anesthesia. Patients may become unresponsive or minimally responsive to vigorous tactile or painful stimulation
- Hypotension may occur. Patients with compromised myocardial function, reduced vascular tone, or those having reduced intravascular volume are at increased risk for hypotension. Keep availability of a secure IV access catheter and supplemental volume replacement fluids during the procedure. Additional pharmacological management may be essential
Cautions: Use cautiously in
- Hepatic impairment
- Cardiovascular disease
- Myocardial dysfunction
- Volume depletion
- Geriatrics
Supplemental Patient Information
- Paresthesias (including burning, tingling, stinging) and/or pruritus may occur upon injection of the initial dose of this drug; inform the patient that these sensations are typically mild-moderate in intensity will last for a short time and will require no treatment
- Advice patients to avoid engaging in activities requiring mental alertness such as operating hazardous machinery, sign legal documents, or driving a motor vehicle during use of this drug
Pregnancy Category:B
Breastfeeding: Unknown whether fospropofol is excreted in human milk; however, propofol is reported to be excreted in human milk, and the effects of oral absorption of fospropofol or propofol are not known. This drug is not recommended for use in nursing mothers.
